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Abstract
Background: Both somatic copy number alterations (CNAs) and germline copy number variants (CNVs) that are 
prevalent in healthy individuals can appear as recurrent changes in comparative genomic hybridization (CGH) analyses 
of tumors. In order to identify important cancer genes CNAs and CNVs must be distinguished. Although the Database 
of Genomic Variants (DGV) contains a list of all known CNVs, there is no standard methodology to use the database 
effectively.
Results: We develop a prediction model that distinguishes CNVs from CNAs based on the information contained in the 
DGV and several other variables, including segment's length, height, closeness to a telomere or centromere and 
occurrence in other patients. The models are fitted on data from glioblastoma and their corresponding normal samples 
that were collected as part of The Cancer Genome Atlas project and hybridized to Agilent 244 K arrays.
Conclusions: Using the DGV alone CNVs in the test set can be correctly identified with about 85% accuracy if the 
outliers are removed before segmentation and with 72% accuracy if the outliers are included, and additional variables 
improve the prediction by about 2-3% and 12%, respectively. Final models applied to data from ovarian tumors have 
about 90% accuracy with all the variables and 86% accuracy with the DGV alone.
Background
Copy number variants (CNVs) are a recently discovered
part of natural genetic variation in humans. CNVs, also
sometimes known as copy number variations or copy
number polymorphisms, is a collective term for dele-
tions, insertions, duplications and large-scale copy num-
ber variants ranging in size between one kilobase and
several megabases [1-4]. About 5-12% of the human
genome, including thousands of genes, may be variable in
copy number, and this variation can be de novo (occur-
ring for the first time in the parent's germ cell) or inher-
ited from the parents by healthy individuals [5,6].
Although their significance is not fully understood, it is
likely that CNVs are responsible for a considerable pro-
portion of phenotypic variation. For example, there are
established links between CNVs and childhood onset of
schizophrenia [7] and autism [8]. It has also been sug-
gested that CNVs can increase the risk of prostate cancer
[9] and neuroblastoma [10]. CNVs contribute to the
understanding of complex diseases through genome-
wide association studies together with SNPs and other
types of variants [11,12]. DNA copy number arrays are
the main instruments for identifying CNVs. The constant
refinement and increasing resolution of these assays is
facilitating the discovery and high precision mapping of
these variants.
Before the importance of CNVs was realized it was well
known that copy number changes occur often in cancer.
Copy number alterations (CNAs) are somatic changes in
genomic copy number of any size, up to a whole chromo-
some, that occur in the genome of a cancerous cell. These
changes often involve important cancer genes such as
tumor suppressor genes and oncogenes. To aid the dis-
covery of important cancer genes, investigators identify
regions that are repeatedly gained or lost in patients with
a particular cancer. CNVs, present in the genome of every
cell, are also present in tumor cells. Thus, when compara-
tive genomic hybridization (CGH) arrays of tumors are
studied, both cancer-related CNAs and germline CNVs
can appear as unique or recurrent changes. It would be
possible to avoid CNVs using a paired tumor-normal
design, with the normal tissue from the same individual
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Page 2 of 13used as a reference. However, if a paired normal sample is
not used or is not available, which is often the case, it is
difficult to distinguish CNAs from CNVs. In addition, it
is possible that the CNVs in the unpaired reference sam-
ple will show up as recurrent events in many or all
tumors.
To our knowledge, there are currently no statistical
methods to identify CNVs in tumor data. A common
practice, recommended, for example, in [13], is to evalu-
ate whether the discovered recurrent regions match
known CNVs in the Database of Genomic Variants (http:/
/projects.tcag.ca/variation) [1], which we call the DGV. It
is unclear, however, to what extent the regions should
match known CNVs. The problems associated with this
practice are that it might exclude unnecessarily big
regions of the genome, and that regions of exclusion will
be imprecise due to uncertainty in the endpoints of the
known CNVs [13]. In addition, smaller CNVs are less
likely to be included into the DGV since they are detected
less frequently in older, low-resolution arrays.
There are other resources available that contain CNVs,
for example CNVVdb (http://cnvvdb.genom-
ics.sinica.edu.tw), DECIPHER (https://deci-
pher.sanger.ac.uk/application/), 1000 genomes project
(http://www.genome.gov/27528684) and dbVAR (http://
www.ncbi.nlm.nih.gov/dbvar/), that eventually may pro-
vide a more comprehensive database. However, for sim-
plicity and clarity, we decided to restrict ourselves to only
one database and chosen the DGV since it was the most
complete and most user-friendly at the time of our analy-
sis. Our goals in this manuscript are twofold. Our first
goal is to determine if additional information can be
added to that from the DGV for predicting CNVs in can-
cer data. Our second goal is to determine how to opti-
mally use the DGV for this same purpose. We are looking
for any characteristics of CNV regions that are different
from cancer-modified segments and thus can be used to
improve prediction. We developed statistical models
toward this goal. These models, in addition to simplifying
data analysis, might allow the discovery of new CNVs
from the abundance of available tumor data.
Our models were developed on Agilent 244 K array
(AG244) data on glioblastoma (GBM) patients from The
Cancer Genome Atlas (TCGA) project [14]. TCGA data
are informative because they include many paired tumor
and normal tissue samples that have been hybridized in
the same manner. Specifically, the tumor samples have
been hybridized against a single reference sample, and
the matching normal samples have been hybridized
against the same reference. Thus, one can identify CNVs
in the normal samples as well as distinguish between
CNAs and CNVs in the tumor samples. We investigate
whether CNVs and CNAs differ in such variables as
length, height, loss/gain status, overlap with changes in
other patients, and other variables. We divide the patients
into training and validation sets, and develop a prediction
model that includes these variables and information in
the DGV. In addition, TCGA has collected copy number
data on several normal tissue samples, which should con-
tain only CNVs, and data from tumor samples co-hybrid-
ized with the patient's own normal tissue reference,
which should contain only CNAs.We use these data, as
well as ovarian TCGA data, to further validate our mod-
els.
The outline of the paper is as follows. In the Methods
section we describe the data and introduce the types of
models that were evaluated. The Results section contains
the univariate and multivariate models and their associ-




We initially selected the first 206 glioblastoma samples
qualified for genomic analyses as part of TCGA [14]. All
of them were hybridized to the AG244 array as well as
other platforms. Here, we limit our analyses to AG244
data collected at the Memorial Sloan-Kettering Cancer
Center(MSKCC). There were 78 patients that satisfied
requirements for our analysis: paired tumor and normal
samples that were independently hybridized against
pooled reference. The normal samples varied between
blood, skin, and muscle tissue. The patient data were
divided into training and test sets by TCGA batch num-
ber in order to maintain the heterogeneity that is likely to
occur in practice. The training set consisted of TCGA
batches 3, 6, and 7, with a total of 43 patients, while the
test set contained batch 5 with 35 patients. The raw data
are of exceptionally high quality and publicly available at
http://cancergenome.nih.gov. The details of the sample
selection and preparation were given in [14]. The collec-
tion of the original material and data of TCGA study was
conducted in compliance with all applicable laws, regula-
tions and policies for the protection of human subjects,
and any necessary approvals, authorizations, human sub-
jects assurances, informed consent documents, and IRB
approvals were obtained.
We originally chose glioblastoma samples to study
CNVs because it was the only set of TCGA patients with
a large enough set of matched samples. As it turns out,
glioblastoma is a disease where distinguishing germline
mutations might prove to be particularly useful because
tumor induced alterations are often of similar size.
Among heterozygous deletions and amplifications that
are present in GBM in at least 10% of patients, as
reported previously [15], 40% are focal alterations, and
about 90% of the rest of them are under 3 Mb. Altered
regions of similar sizes are reported in the TCGA manu-
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Page 3 of 13script [14]. In fact its authors excluded regions as CNVs if
they 1) appeared to be CNVs in HapMap normals, or 2)
appeared in at least 2 independent publications in DGV,
or 3) appeared in the matched normal tissue by manual or
automated search. These exclusion criteria are compli-
cated and would be difficult to replicate. We developed a
model that would simplify such an analysis.
As TCGA progressed some of the data for ovarian can-
cer became available. We downloaded 38 pairs of
matched normal and ovarian tumor samples hybridized
at MSKCC. These data were used to validate our models.
Segmentation analysis
The raw log-ratio data were normalized as described in
the supplementary section of the TCGA manuscript [14].
To identify possible regions of gain and loss, we seg-
mented the normalized log ratios using two different
algorithms: CBS and GLAD. CBS, or Circular Binary Seg-
mentation [16,17] is a method for segmenting data into
regions of equal estimated copy number. It has been
found to have good properties compared to other similar
methods (see [18,19]), and is included in the Bioconduc-
tor package DNAcopy (http://www.bioconductor.org).
We have used all default parameters, including the signif-
icance level of α = 0.01, except for the minimum gap
between the segments was set to be one standard devia-
tion (undo.sd = 1). Users frequently apply a smoothing
procedure to remove outliers from the data prior to seg-
mentation, which can increase power and remove some
smaller gains and losses. On the other hand, smaller
regions eliminated by smoothing may contain CNVs.
Therefore, we fit the prediction model on both smoothed
and non-smoothed data.
Alternatively, we estimated intervals of change using
the GLAD algorithm [20], Bioconductor package GLAD)
with default parameters. GLAD automatically filters out-
liers, analogous to smoothing in CBS. The second
method was used to ensure that the accuracy of the pre-
diction model was not specific to a particular segmenta-
tion method. Both of these methods are frequently used
for segmenting cancer data.
Candidate CNVs
The unit of analysis for us is a segment of constant copy
number with breakpoints estimated by one of the seg-
mentation algorithms described previously. We are call-
ing any segment a gain or loss that has an average log
ratio of at least one median absolute deviation above or
below the array's median, respectively. Segments within
this range are called normal.
Suppose only tumor data were available. Then long
enough gains and losses would not be confused with
CNVs, since CNVs are not longer than several
megabases. Likewise, if a segment of interest is in the
midst of larger gains or losses, it is difficult to identify
whether it was modified in the germline. Therefore, we
consider every segment of gain or loss in the tumor that
has length of up to 2.3 megabases AND is flanked by at
least one normal segment to be a candidate CNV for our
classification model. This definition reproduces the situa-
tion where the question of identifying CNVs might arise.
Consecutive gains or consecutive losses were combined
if their total length was under 2.3 Mb. The upper thresh-
old for length was motivated by the analysis of true CNVs
from the normal samples, i.e. 2.3 Mb was roughly the
maximum of observed CNVs in the normal samples.
Note that CNVs of greater length than this are reported
in the literature; however, they comprise less than 1% of
reported CNVs, and might have characteristics vastly dif-
ferent from the majority. Although by formal definition
CNVs have to be at least 1 kb in length as stated by [3], we
did not use this restriction. Since the gap between probes
was often large and segment lengths were possibly under-
estimated, we have included the few segments that were
shorter than 1 Kb. Chromosomes X and Y were excluded
from consideration. Any candidates located in the "physi-
ological" regions shown in Additional file 1, Table S1 were
also excluded following suggestion by [21]. Physiologic
CNVs reflect normal somatic rearrangements that occur
in the immunoglobulin genes and T-cell receptors during
their development [22-24].
The matching normal samples were processed and seg-
mented in exactly the same fashion as the tumor samples.
They were used to determine which of the candidate
CNVs were true CNVs. For example, consider Figure 1.
All the red segments of gain and loss were found by
smoothed CBS on one chromosome; in addition, the blue
Figure 1 Example of CNVs and CNAs. One chromosome is shown. 
Segments in blue are found only in unsmoothed data. The upper panel 
contains tumor, while the lower panel is a matching normal sample. 
CNVs have either a matching segment in the normal sample identified 
by a segmentation algorithm or matching significantly extreme log-ra-
tios identified by a permutation test. Regions of the normal sample 
corresponding to CNAs are normal.
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top and bottom panels represent a tumor and the corre-
sponding normal tissue. If a gain or loss in a tumor sam-
ple exactly matched a gain or loss in a normal sample, it
was considered a true CNV. However, the segmentation
algorithm introduced error in estimation of the break-
points, so even true CNVs might not exactly match
between the samples. For example, the red segment
marked as CNV overlapped with the matching loss in the
normal sample that did not have exactly the same break-
points.
Furthermore, some segments in the normal sample
might not make it to the required threshold of signifi-
cance and thus would not be identified by the segmenta-
tion algorithm. In the figure it can be seen that there is an
extremely low log ratio (outlier) in a normal sample cor-
responding to the last candidate loss (in blue) in the
tumor, but it is not extreme or long enough to be identi-
fied by CBS. To ensure that such segments were not
missed we perform a conditional segmentation test for
each candidate CNV. In this test we consider log-ratios in
the normal sample corresponding to the candidate seg-
ment in a tumor. Suppose there are k of them. First we
calculate their mean μ. Then we randomly draw k values
from the pool of normal sample log-ratios that are
located within the candidate and two of its neighboring
segments in the tumor and calculate their mean this pro-
cedure is repeated 1000 times. If the mean of normal log-
ratios corresponding to the candidate segment μ exceeds
the gain/loss threshold and is less extreme than the simu-
lated means μ* in less then (α = 0.01 × 100)% of draws, we
declare the candidate to be a true CNV.
In summary, each gain or loss candidate CNV is con-
sidered a true CNV if it overlaps a gain or loss in a normal
sample identified by a segmentation algorithm, or if the
mean of the corresponding segment in the normal sample
is significant by the conditional segmentation algorithm
described above. Otherwise the candidates are consid-
ered to be CNAs.
The blue segments in Figure 1 illustrate the trade-offs
associated with unsmoothed data. On one hand, one
additional CNA and three CNVs emerge when outliers
are included in the segmentation. On the other hand,
some of these new candidates appear as a result of just
one extreme marker. Unless there are array artifacts, it is
unlikely that the outliers will simultaneously occur in two
arrays in exactly the same probe, and that gives us confi-
dence that unsmoothed data can be useful. However,
whenever such data are used the results have to be vali-
dated in order to guarantee that the extreme markers are
not array artifacts. True CNV status for each candidate
CNV is a response variable in our model. The predictors
for our model are discussed below.
Database of genomic variants
As mentioned before, previously discovered CNVs are
reported in the DGV. This database has been used before
to distinguish CNAs from CNVs (e.g. [14], but there is no
standard quantitative way to make this distinction. In
addition, there is some uncertainty in the breakpoints in
the reported CNVs. We propose to quantify the overlap
with the DGV in the following way. For each probe we
calculate the total number of reported variants (unique
Variation IDs) that include it. Then, for each candidate
CNV its Database score is defined as average number of
these reported variants across all the probes that com-
prise it. The resulting number is not usually an integer
since most overlapping regions in the database do not
have the same breakpoints. The less a candidate segment
overlaps known CNVs in the DGV, the smaller its Data-
base score.
Alternatively, instead of the number of variants we used
the total reported number of people that had variants
overlapping a probe, and this score is called Database
score II. This variable is potentially informative because
each variant from the DGV has different frequency.
The DGV is updated regularly. For our analysis, we
used version 7 of the database for genome build 'hg18'
from March 2009 available at http://projects.tcag.ca/vari-
ation/downloads/variation.hg18.v7.txt.
Predictors
Detailed definitions of the candidate predictors for our
models are presented in Table 1. These predictors were
derived from published results, biological intuition and
observations from studying the data. We divide predic-
tors in three categories: "demographic", "derived" and
"spatial".
"Demographic" variables are the basic characteristics of
the candidate segment, such as its length (in bases), abso-
lute value of segment mean (raw or adjusted by the noise
level), gain or loss status, and difference between segment
means of two nearby segments adjusted by the noise
level. We have also included indicator variables for
whether a candidate is surrounded by all normal seg-
ments, is within 2 MB of centromere or telomere [25], or
overlaps any of the known areas of segmental duplication
[26]. A "derived" variable uses information from arrays of
other independent patients of the same study. The most
important of these variables records what percentage of
other tumors also have a candidate CNV in the same
location, and whether it is a gain or a loss. Since the
breakpoints are estimated with error we used two ver-
sions of the same predictor, counting other patients with
the segments that either overlap the candidate segment
or have at least one of the breakpoints exactly matching.
If other patients have both gains and losses in the same
location, it is likely that this alteration is a CNV. Similarly,
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gains (or losses) are frequent is likely to be a CNA.
A "spatial" variable captures possible association of
CNVs with other segments located on the same chromo-
some such as percentage of the chromosome that is
gained or lost, existence of nearby candidates and average
Database score of the other candidates on the same chro-
mosome.
Statistical methods
The response variable in our model is binary, whether a
candidate region is a CNV or CNA, while predictors are
either binary, multi-level factors, or continuous. To
examine the univariate relationship between CNV status
and the predictors we utilized univariate logistic regres-
sion because it can accommodate variables of all types
and provides us with both significance levels and esti-
mates of the effects. Multivariate logistic regression,
Table 1: Definition of predictors.
Variable-Definition
Length - length of a segment in bases
Segmental duplication - 1 if the candidate is overlapping known region of segmental duplication, 0 otherwise. All regions listed in [32] that could 
be successfully translated into hg18 by hgLiftOver utility http://genome.ucsc.edu/cgi-bin/hgLiftOver were used, see Additional file 1, Table S2
Closeness to centromere - 1 if the candidate endpoints are within 2 Mb of the centromere, 0 otherwise
Closeness to telomere - 1 if the candidate endpoints are within 2 Mb of the telomere, 0 otherwise
Sign - 1 if the candidate is a gain, -1 if it is a loss
Height - absolute value of the candidate segment mean
Relative height - absolute value of the candidate segment mean divided by the median absolute deviation of the array residuals
Break - absolute di_erence between means of two segments surrounding the candidate divided by the median absolute deviation of the array 
residuals
Surrounded by Normals - 1 if both surrounding intervals are normals, 0 if one of them is a gain or a loss
Overlap with other patients - factor with levels: GG if there is one or more other patients in the cohort that have overlapping candidates, all of them 
are gains; LL if there is one or more other patients in the cohort that have overlapping candidates, all of them are losses; GL if there are at least 
two patients with overlapping candidates, some of them are gains and some are losses; None if there are no other patients with overlapping 
candidates
Overlap with other patients - percent - proportion of other patients in the cohort that have overlapping candidate
Matching breakpoint in other patients - percent - proportion of other patients in the cohort that have a candidate with at least one exactly matching 
breakpoint
Close to other candidates - 1 if there is another candidate CNV within 500 kb on the same chromosome in this patient
Percent of Normal - percent of markers on a chromosome where candidate is located that are not lost or gained
Database score of other candidates - average Database score of other candidates on the same chromosome
Overlap with CNAs - number of other patients that have overlapping non-candidate segment of the same sign as the candidate (gain or loss)
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highly collinear.
Classification and Regression Trees (CART) is a suit-
able alternative for highly collinear data [27]. CART is a
binary tree approach that is based on recursively splitting
on the most predictive variable. CART trees are simple to
interpret and have the ability to uncover complex rela-
tionships among correlated predictors. One of the disad-
vantages of CART is that it is often not optimal in terms
of prediction error, partly because it is greedy (no looking
ahead before splitting). Therefore, we have also used ran-
dom forests (RF) [28]. RF are a modification of CART
that overcome CART's search difficulties by building
multiple trees based on resampling cases. Classification is
based on the "votes" of each of these trees. These trees
further differ from CART trees because only a random
set of predictors is considered at each split. Although this
algorithm tends to lead to prediction accuracy that is
superior to CART [28], the results of RF are more diffi-
cult to visualize and interpret. Therefore, we used both
CART and RF. CART and RF were implemented using
the R packages rpart and randomForest, respectively.
CART models were pruned according to the "1-SE" rule.
All the analyses were performed in R (http://www.r-
project.org/) and the final RF models are collected in an
RData file, which is available online along with a short
manual.
Results
All the analyses were performed on three data sets:
smoothed CBS, GLAD and unsmoothed CBS. In the
training data set they contained 1448, 1624 and 2037 can-
didate segments, respectively, and 904 (62%), 744 (46%)
and 1448 (71%) of them were considered true CNVs. The
samples in the test set accounted for 1683, 1738 and 2686
candidates and 939 (56%), 846 (49%) and 1727 (64%) true
CNVs respectively. There are 638 (510) and 761 (674) seg-
ments in the training and test set respectively that are
true CNVs (true CNAs) in both smoothed CBS and
GLAD, therefore the overlap between smoothed CBS and
GLAD is very substantial. The training set contained
more patients than the test set but it contained fewer can-
didate segments. This can be explained by the fact that
the training set had slightly noisier arrays (higher MAD of
residuals), and, therefore, there was less power to detect
smaller segments.
Univariate results
To test association of predictors with true CNV status we
pooled the training and test sets. The results within these
sets separately were very similar and are not presented.
Table 2 contains both Anova p-values and regression β
coefficients.
The smoothed CBS and GLAD had very similar rank-
ings of significant predictors and their effects. As
expected, Database score had the most significant p-
value, followed by Matching breakpoint in other-patients
- percent in CBS or Overlap with other patients - percent
in GLAD, Length, and Percent of Normal. All other pre-
dictors were also significant. Obviously, overlap with
many variants from the DGV was a strong positive pre-
dictor of being a CNV. Segments that were shorter,
matched with candidates from many other patients or
overlapped with both gain and loss candidates in other
patients were also more likely to be CNVs. Having other
patients with overlapping candidate losses only was also a
positive predictor. As seen from the direction of the main
effects in Table 2, CNVs tended to have larger absolute
values of segment means; were often surrounded by Nor-
mal segments; located on chromosomes with fewer gains
and losses, or with other candidates with high Database
score; or located close to a telomere, centromere or seg-
mental duplication. Also, we saw several clusters of small
CNAs right next to each other, so presence of other can-
didate segments within 500 kb was predictive of CNA.
In unsmoothed CBS the strongest predictor was Over-
lap with other patients, followed by the Database score.
One possible explanation for this difference is that the
small CNVs are underrepresented in the DGV but are
likely to appear in the unsmoothed arrays of other
patients in the cohort. The other notable difference with
smoothed segmentation is that closeness to a centromere,
telomere or segmental duplication were not significant,
possibly because longer CNVs tend to be located there. In
fact, the interaction term between length and closeness to
centromere (or segmental duplication) was significant in
logistic regression for both smoothed and unsmoothed
CBS. As demonstrated by the interaction effect, segments
at these locations and of longer length were even more
likely to be CNVs.
Note that these associations are not causal, and the
mechanisms by which CNVs occur and fixate in the pop-
ulation are still to be elucidated.
Prediction models
We have fitted prediction models using smoothed CBS,
GLAD and unsmoothed CBS with 4 different sets of pre-
dictors. Accuracy was defined as the percentage of cor-
rectly classified candidate segments among all CNV
candidates in all tumor samples of validation set. Accu-
racy was evaluated on 3 validation sets. The full set of
predictors contained all the variables described in Table 2
except Database score II and Height that were nearly
equivalent to the already included variables Database
score and Relative height. We first will discuss the results
based on smoothed CBS. The fitted CART model
selected only five predictors, as is shown in Figure 2. The
Ostrovnaya et al. BMC Bioinformatics 2010, 11:297
http://www.biomedcentral.com/1471-2105/11/297
Page 7 of 13first split was made on the Database score: if the probes
in the candidate segment were included in the DGV at
least 2.45 times on average, the candidate was predicted
to be a CNV. Otherwise, only segments with the follow-
ing characteristics were predicted to be CNVs: 1) seg-
ments shorter than 30 Kb; or 2) segments of length longer
than 30 Kb that had matching candidate segments in 37%
or more of the other patients. The prediction accuracy of
this model, estimated for the smoothed CBS test set, was
86%, as shown in Table 3. Table 4 has the numbers of can-
didate segments that were correctly and falsely classified.
There were 793 true CNVs predicted to be CNVs, and
654 correctly identified true CNAs. Interestingly, number
of CNAs falsely identified as CNVs (182) was much
higher than number of missed CNVs (54). We believe
CNVs were easier to identify because the DGV contains
extensive information about them.
The two other validation sets we used were the set of 39
tumors that were hybridized against self-reference, so
that all its 1780 candidates were considered true CNAs,
and the set of 8 normal tissue arrays, so that all its 257
candidates were considered true CNVs. As seen in Table
3, 79% and 90% of these segments, respectively, were
identified correctly. As in the test set, the rate of missed
CNVs was smaller.
The RF model with the same set of predictors increased
the accuracy by 1% on the test set, and by 3-5% on the 'all
CNAs' and 'all CNVs' sets. Since the best model was a
combination of many trees it is difficult to display; how-
ever, relative importance of each variable measured by
Gini index is shown in Table 5. The more influential vari-
ables have higher indices. The ranking of the variables
was roughly consistent with univariate results: the top
predictors were Database score, Length, Matching break-
point in other patients -percent, Overlap with other
patients - percent, Percent of Normal and Relative height.
We have also fitted the CART model with a single vari-
able - Database score. Its only split was the same as the
first split of the full model: segments seen in the DGV on
average 2.45 times were predicted to be CNVs. The pre-
diction accuracy of this model was equal to 85%, 88% and
81% on the test, 'all CNAs' and 'all CNVs' sets respec-
tively. Therefore, using all the proposed predictors on the
test set in addition to the Database score increased the
accuracy on the test set by 2%. As can be seen from Table
4, the sensitivity of the full RF model is 82%, which is
Table 2: Univariate results by logistic regression, training and test sets combined.
Smoothed CBS GLAD Unsmoothed CBS
β P β P β P
Height 3.95E - 01 1.16E - 20 4.88E - 01 7.93E - 27 8.88E - 01 6.47E - 117
Relative height 7.14E - 02 3.36E - 17 9.34E - 02 9.75E - 26 1.64E - 01 7.79E - 102
Break -3.43E - 01 1.06E - 24 -3.39E - 01 2.47E - 26 -3.42E - 01 3.33E - 36
Close to other candidates -1.19E + 00 2.17E - 32 -8.06E - 01 6.78E - 17 -1.17E + 00 1.19E - 37
Overlap with CNAs -7.10E - 02 1.24E - 26 -6.67E - 02 6.88E - 25 -5.07E - 02 9.44E - 22
Database score 3.06E - 01 4.08E - 306 3.06E - 01 1.98E - 323 2.27E - 01 8.60E - 186
Database score II 9.79E - 03 3.19E - 159 9.35E - 03 2.16E - 167 5.90E - 03 5.25E - 74
Overlap w. other pts: % 8.89E + 00 4.98E - 254 8.02E + 00 8.64E - 276 5.45E + 00 1.71E - 158
Matching bkpt in other: % 17.31 2.58E - 276 13.13 1.11E - 246 9.14 3.62E - 178
Overlap w. other pts - GG 3.42E - 01 3.63E - 199 3.37E - 01 1.04E - 208 -1.70E - 01 6.08E - 258
LG 2.85E + 00 2.85E + 00 2.29E + 00
LL 1.68E + 00 1.73E + 00 2.13E + 00
Closeness to centromere 8.41E - 01 2.55E - 09 7.98E - 01 2.72E - 09 7.15E - 02 5.95E - 01
Closeness to telomere 4.24E - 01 2.15E - 04 5.78E - 01 2.46E - 07 -1.55E - 01 1.27E - 01
Length -2.46E - 06 2.14E - 130 -1.78E - 06 9.65E - 94 -2.65E - 06 1.27E - 183
Dat. score of other cand. 5.98E - 02 6.69E - 17 5.45E - 02 9.41E - 14 5.17E - 02 9.02E - 11
Percent of Normal 3.40E + 00 5.29E - 59 2.70E + 00 3.35E - 50 2.78E + 00 1.72E - 60
Segmental duplication 6.81E - 01 5.71E - 11 7.16E - 01 1.51E - 13 1.79E - 01 5.85E - 02
Sign -2.74E - 01 5.10E - 14 -2.62E - 01 2.73E - 13 -7.05E - 01 2.06E - 107
Surrounded by Normals 1.30E + 00 2.28E - 23 1.07E + 00 5.02E - 23 1.31E + 00 7.06E - 32
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Page 8 of 13slightly lower than the 84% sensitivity of the Database
score only model. The specificity, however, of the full RF
model is much higher: 94% compared to 85%.
The fitted CART tree was different using GLAD,
although the first split was still made on the Database
score. As seen in panel (b) of Figure 2, segments were pre-
dicted to be CNVs if 1) they were included in the DGV at
least 3 times on average and had relative absolute mean
greater than 1.5; or 2) they were included in the DGV less
than 3 times on average and overlapped with other candi-
dates in at least 38% of other patients of the cohort. In the
RF model for GLAD, the 6 variables with the highest Gini
indices (Table 5) were the same as in smoothed CBS,
while having slightly different ranking. In spite of these
differences, the prediction characteristics of models
based on GLAD and smoothed CBS were similar. The RF
with all predictors correctly identified 86% of candidates
in the test set, 91% of 1861 true CNAs in 'all CNA' data-
set, and 87% of 247 true CNVs in 'all CNVs' set, while the
rates of false CNVs and false CNAs were more balanced.
The model with only Database score had the same first
split of Database score greater or less than 3, and its accu-
racy on the test set was only 3% smaller than that for the
full model. For GLAD, the sensitivity was 82% and 78%
for the full RF and Database score only models respec-
tively, while the specificity was 90% and 87%.
Since many of the predictors were highly correlated
there could be many classification trees with similar pre-
diction accuracy, so the difference in models between
GLAD and smoothed CBS might be a result of random
variation rather than fundamental segmentation differ-
ences. In fact, when we applied the full RF developed on
the GLAD segmented training set to the smoothed CBS
test set, the prediction accuracy was 87%, which was the
same as the model developed based on smoothed CBS.
Similarly, the RF developed on the smoothed CBS train-
ing set resulted in 83% accuracy when assessed on the
GLAD test set, which was just 3% lower than the RF
developed on the GLAD training set.
Prediction modeling based on unsmoothed CBS had
several important differences. The variable Matching
breakpoint in other patients - percent served as the first
split in the classification tree. If a segment 1) had candi-
dates with matching breakpoints in more than 1.2% of
other patients and was either shorter than 396 Kb or was
both longer than 396 Kb and was included in the DGV on
average 4.5 times; or 2) had candidates with matching
breakpoints in less than 1.2% of other patients, was
shorter than 22 Kb, or shorter than 77 Kb and included in
the DGV on average 1.3 times, or longer than 77 Kb and
included in the DGV on average 3.1 times, then it was
predicted to be a CNV. Note that in our training set the
first split is equivalent to having at least one other tumor
with breakpoint exactly matching the breakpoint of a
candidate. RF had the same 6 variables with the highest
Gini indices as two other segmentation methods, and it
Figure 2 Fitted CART models.
Table 3: Prediction rates: A - test set, B - CGH against self-reference (all CNAs), C - normal tissue (all CNVs).
CBS smoothed GLAD CBS unsmoothed
A B C A B C A B C
CART-full model 0.86 0.79 0.90 0.83 0.91 0.78 0.80 0.66 0.92
RF - full model 0.87 0.82 0.95 0.86 0.91 0.87 0.84 0.77 0.92
CART- database only 0.85 0.88 0.81 0.83 0.89 0.80 0.72 0.34 0.99
RF - no database 0.85 0.79 0.94 0.86 0.89 0.85 0.82 0.74 0.95
RF - one array 0.85 0.81 0.97 0.84 0.91 0.89 0.83 0.75 0.96
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Page 9 of 13correctly predicted 84% of segments in the test set, as
well as 77% of 1785 CNAs and 92% of 464 CNVs in the
two other validation sets. Unlike in smoothed CBS and
GLAD, the classification tree that included only Data-
base score showed only 72% accuracy on the test set, 12%
lower than the full model. The sensitivity was 83% and
69% for the full RF and Database score only models
respectively, while the specificity was 86% and 91%. This
model had a much higher false CNV rate - 66% of all
CNAs in the test set and 66% of the CNAs in 'all CNAs'
validation set were falsely identified as CNVs (see Tables
3, 4). We speculate that unsmoothed CBS contained
smaller intervals that rarely appeared in the DGV, and the
Database score was less informative about them. As a
result the model had lower prediction rates on the valida-
tion sets.
While the DGV provided the strongest univariate infor-
mation, we investigated whether it was absolutely neces-
sary for predicting CNVs by fitting RF that excluded
Database score and Database score of other candidates.
We saw only a modest drop in prediction accuracy of 0-
2%. The most important variables suggested by the Gini
index Matching breakpoint in other patients - percent,
Overlap with other patients -percent, Length, Relative
height, and Percent of Normal were the same across all
three segmentation methods.
Since Overlap with other patients and Overlap with
CNAs are only informative when there are multiple
Table 4: Counts from the accuracy table of the test set.
CBS smoothed GLAD CBS unsmoothed
TN FN FP TP TN FN FP TP TN FN FP TP
CART-full model 654 54 182 793 822 145 157 614 613 77 455 1541
RF - full model 659 42 177 805 828 93 151 666 752 124 316 1494
CART- database only 699 120 137 727 804 122 175 637 364 37 704 1581
RF - no database 644 57 192 790 824 91 155 668 686 112 382 1506
RF - one array 647 59 189 788 832 125 147 634 729 120 339 1498
(TN, True Negatives, are true CNAs predicted to be CNAs; FN, False Negatives, are true CNVs predicted to be CNAs; FP, False Positives, are true 
CNAs predicted to be CNVs; TP, True Positives, are true CNVs predicted to be CNVs)
Table 5: Relative importance of variables in random forest models as measured by Gini index (higher is more important).
CBS smoothed GLAD CBS unsmoothed
Variable w. DS w/o DS w. DS w/o DS w. DS w/o DS
Relative height 60.33 79.86 81.26 100.96 101.99 119.94
Break 39.98 51.92 48.57 65.75 60.33 72.19
Close to other candidates 8.27 10.83 4.18 6.90 6.19 8.20
Overlap with CNAs 17.21 24.15 17.87 27.10 26.16 34.09
Database score 165.44 206.34 108.89
Overlap w. other pts: % 70.11 107.05 95.23 129.03 74.62 93.67
Matching bkpts in other: % 86.67 108.45 94.02 135.80 116.34 116.83
Overlap with other pts 39.91 59.70 42.18 68.84 86.42 98.28
Closeness to centromere 4.37 5.82 3.74 6.07 4.64 7.17
Closeness to telomere 4.65 6.53 3.31 5.52 6.04 7.11
Length 112.20 133.69 64.26 92.25 170.78 182.46
Dat. score of other cand. 30.23 32.57 44.51
Percent of Normal 64.10 84.05 55.97 76.26 77.18 93.82
Segmental duplication 3.19 7.77 3.48 9.53 5.16 9.34
Sign 7.84 11.01 8.19 12.42 22.59 27.77
Surrounded by Normals 1.87 4.67 5.03 6.66 3.34 5.21
"'W. DS"' stands for the model that includes Database score (DS), "'w/o DS"' stands for the model where it was excluded.
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Page 10 of 13patients in the cohort, we have also considered models
without these variables since they could be applied to sin-
gle arrays. They are presented in the last row of Tables 3
and 4. There was a 1-2% loss of accuracy compared to the
full models.
The accuracy measure in Table 3 represents per-study
error rate where all potential CNVs in all tumors are
pooled together. Note that CNVs that appear in many
patients will have a higher chance of being correctly clas-
sified compared to the rare CNVs. Thus, per-variant
accuracy might be lower on average than per-study accu-
racy. We do not estimate the per-variant error rate since
it is not clear how to classify observed segments into dis-
tinct variants. Another accuracy metric we considered
was per-tumor accuracy. The median per-tumor accu-
racy rates are shown in the Additional file 1, Table S3 and
are very similar to per-study accuracy rates.
Since, as we mentioned, training set had slightly noisier
arrays, we have also examined whether switching training
and validation sets would lead to different results. The
accuracy rates were in fact similar to those shown in
Table 3. For example, the accuracy of the full RF model
and model with Database score only developed on the
former testing set and tested on the former training set,
was 86% and 81% respectively for smoothed CBS, 88%
and 84% for GLAD, and 88% and 78% for unsmoothed
CBS. Thus, the full model gives similar advantage com-
pared to the Database score only as seen previously.
While the basic CART model with just Database score
works fairly well, we have tested it against the basic ad-
hoc rule often used in the literature: a candidate CNV is
classified as CNV if it overlaps variants reported in the
DGV from at least two different studies (manuscripts),
and it is a CNA otherwise. Based on the combined train-
ing and testing set (there is no model development), this
ad-hoc rule identified correctly 65%, 62% and 60% candi-
dates in smoothed CBS, GLAD and unsmoothed CBS
respectively, significantly fewer than CART Database
score only.
Validation using ovarian dataset
We expect the models to be valid across all cancers as
long as few CNVs are associated with cancer. To verify
this we obtained 38 pairs of matched normal and ovarian
cancer samples from the TCGA website. They were seg-
mented using smoothed CBS only, the method we pre-
dominantly use in practice. Since they were already
smoothed during the normalization process,
unsmoothed segmentation was not performed. There
were 2623 candidate CNVs in the tumor samples of
which 485 were called true CNVs by the same algorithm
that was used for glioblastoma data. The models devel-
oped based on smoothed CBS and GLAD segmentation
have prediction accuracy of 86% and 87%, respectively, if
they contain the DGV information only, and 89% and
90% if all predictors are utilized. As in the GBM data, the
error rates of the full smoothed CBS model are unbal-
anced: 230 CNAs predicted as CNVs and 70 missed true
CNVs, with 1908 and 415 correctly identified CNAs and
CNVs. The errors are well balanced for the GLAD-
derived model; the respective counts are 134, 137, 2004
and 348. Thus, a model derived from GLAD-segmented
glioblastoma data offers about 90% prediction accuracy,
which is 3% higher than the DGV only model, as well as
balanced error rates, even in ovarian cancer data.
Discussion
In this article we introduced a framework for distinguish-
ing germline copy number variants (CNVs) from cancer-
related copy number alterations(CNAs) when analyzing
tumor samples on copy number arrays. To our knowl-
edge, our manuscript is the first attempt to quantify the
overlap of a given copy number abnormality with the
database of genomic variants (DGV) and to suggest a rule
for determining CNVs. We have also examined various
characteristics of the altered segments that can differ
between CNVs and CNAs. We considered three segmen-
tation methods to identify candidate CNVs and built
CART and RF prediction models using up to 16 predic-
tors that can be applied to both cohorts of several inde-
pendent patients and to single arrays. If the segmentation
was done after removing outliers then the most impor-
tant predictor was overlap with DGV. If each probe of a
candidate segment overlapped on average with 2.5 - 3
variants listed in the DGV, this candidate segment was
likely to be a CNV. Inclusion of additional variables like
Length, Relative height, Overlap with other patients in the
cohort improved the accuracy by a few percent. The
model developed using one segmentation method can be
successfully applied to another equivalent segmentation
method (smoothed CBS and GLAD). The advantage of
additional predictors was more pronounced (12% higher
accuracy) if the segmentation was performed on data
with no outliers removed. Such data were more likely to
contain smaller candidate segments that are missed in the
DGV.
Overall, the prediction accuracy in the test set is
around 85% across different segmentation methods. We
have also applied the classification algorithm to valida-
tion sets containing only CNVs (normal samples) or only
CNAs (tumor samples with CNVs subtracted as a refer-
ence). The candidate segments were correctly classified
in these datasets in 80-95% of cases, even though our
classification model was not developed on these types of
samples. The prediction accuracy of the full model evalu-
ated on the smoothed CBS ovarian data set was 90%.
Note that the variable Database score, while being one
of the most significant, is based on the DGV, which has
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Page 11 of 13some inaccuracies and repetitions. For each probe it
involves the count of variants listed in the DGV that cov-
ered that probe. These variants, however, are not inde-
pendent and the representation of many of them in the
DGV is redundant. For example, many studies report
identical or almost identical variants observed on the
same sets of patients (e.g. HapMap patients), and a few
variants are listed twice even within the same study. In
addition, variants have been observed in a different num-
ber of people and have different frequencies, although
our variable Database score II that utilized these frequen-
cies did not prove to be superior, probably also due to
redundancy in variant reporting. All other modifications
of the Database scores that we tried, including a score
that used the percentage of people that exhibited the vari-
ant in each study, did not offer the improvement in the
prediction rates. Note that CNVs discovered by fine scale
mapping of DNA from HapMap patients [29] were much
smaller, often by more than 50%, than CNVs reported in
the DGV based on previous studies. Also, many variants
that were discovered using lower resolution assays like
BAC arrays were likely to have inaccurate endpoints;
however, excluding BAC arrays from the calculation of
the Database score did not improve the prediction. As the
DGV and the frequencies of all known CNVs become
more accurate, it may be possible to improve the predic-
tion model. Although we have identified true CNVs by
matching the candidate segments in tumors to their cor-
responding normal samples, our classification is not a
gold standard. Due to stromal contamination, segmenta-
tion error and possibly imperfect gain/loss calling, some
CNVs and CNAs in the tumors might have been missed.
It is also plausible that some true CNVs were missed by
our matching method and classified as true CNAs. How-
ever, since we have verified the prediction framework on
several validation sets, we do not expect the error in true
CNV classification to have had a major impact on the
model. We also believe that the fitted models are not spe-
cific to glioblastoma since CNVs should be mostly homo-
geneous across patients with different cancers, and the
good predictive ability on the set of ovarian cancer sam-
ples and on the normal samples supports this claim.
A possible feature that could help identify CNVs is eth-
nicity. We know that CNV proportions vary by ethnic
group [30]. However, the early TCGA data on which we
have built our models is mostly Caucasian, so it is not
currently possible to use ethnicity. One mitigating factor
is that the DGV includes CNVs from many populations,
and variables (e.g. length, height) that differ between can-
cer CNAs and CNVs in Caucasians would be expected to
have the same relationships across ethnic populations.
Our models do not depend on the scale of log-ratios
since the only important predictor that depends on them,
absolute segment mean, is divided by the median abso-
lute deviation of noise and as a result, Relative height is
scale and noise level invariant. Nevertheless, all our anal-
yses are done on Agilent 244 K arrays, and CNVs might
have different characteristics if they were detected on
arrays of different resolution or different platforms. We
believe that the model will be as efficient on arrays that
have similar or worse quality and resolution, since they
likely identify CNVs that are similar to or a subset of what
can be found by the Agilent 244 K platform.
The Agilent 244 K array, like all non-SNP arrays, mea-
sures total copy number rather than allele-specific copy
number. That is, it cannot separately estimate the two
parental copy number contributions. This could lead to
occasional error in our analysis. For instance, if there
were CNVs on both alleles, and if there were a somatic
copy neutral LOH event (one parental copy number dou-
bles while the other disappears) that was larger than the
CNV event, it is possible that we would interpret this
event as a CNA (which would be correct), a CNV, or a
normal region depending on the combination of copy
numbers on two alleles in the CNV. The interpretation
would depend on the allelic copy numbers of both the
normal and tumor samples. This problem, however, is
due to the limitation of the array, not to our algorithm.
Many studies that have the goal of identifying cancer
genes deliberately exclude CNVs prior to analysis (e.g.
[14]. One way to do this using our algorithm would be to
segment the original data and apply the appropriate RF
model. The probes within predicted CNVs in at least one,
or, conservatively, several patients could be excluded, and
the reduced data set could be segmented again for the
final analysis. Alternatively, since predictions are
obtained for all segments that are located in areas of sus-
pected recurrent gain or loss, a region might be discarded
if some or many of the matching candidates are predicted
to be CNVs.
It is also interesting to study CNVs in cancer patients.
For example, there is evidence that CNVs may contribute
to chromosome breakage [31] and to cancer risk [9,10].
There are abundant studies of copy number on cancer
patients that are publically available. For any of these
studies the data can be segmented and all the candidate
segments can be classified as CNVs or CNAs. Assuming
no CNVs from the reference sample appear in the
tumors, the presence of CNVs as identified by the pro-
posed method can be correlated with recurrent CNAs or
clinical characteristics. Therefore, the classification
model that we developed may facilitate the study of the
associations between CNVs and cancer predisposition or
progression.
Conclusions
We have developed several prediction models that distin-
guish germline copy number variants (CNVs) from can-
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Page 12 of 13cer-related copy number alterations (CNAs) based on
copy number arrays of tumor samples with no matching
normal sample. Using the Database of Genomic Variants
alone CNVs in the test set can be correctly identified with
about 85% accuracy if the outliers are removed before
segmentation and with 72% accuracy if the outliers are
included, and additional variables improve the prediction
by about 2-3% and 12%, respectively. Final models applied
to data from ovarian tumors have about 90% accuracy
with all the variables and 86% accuracy with the DGV
alone. Based on the accuracy rates, we recommend the
full RF model developed using unsmoothed CBS to iden-
tify CNVs for datasets that contain outliers, while we rec-
ommend the full RF model developed using GLAD for
datasets in which the outliers have been removed.
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